<DOC>
	<DOCNO>NCT00683085</DOCNO>
	<brief_summary>Pancreatic cancer fourth lead cause cancer death United States , combination therapy far superior gemcitabine alone . Vascular endothelial growth factor receptor type 1 ( VEGFR1 ) express tumor vessel candidate tumor vessel-specific peptide vaccination strategy induce T cell immune response . We conduct study confirm safety efficacy combine modality intervention use conventional dose gemcitabine peptide vaccination target tumor-vessel specific VEGFR1 case advanced/inoperable therapy-resistant pancreatic cancer patient . Gemcitabine 1,000 mg/m^2 ( body surface area ) administer day 1 , day 8 , day 15 , day 29 , day 36 , day 43 , respectively . VEGFR1-derived HLA-A*02:01-restricted peptide ( VEGFR1-A02-770 ; TLFWLLLTL ) emulsify Montanide ISA51 subcutaneously inject twice weekly 8 week ( total 16 dos ) .</brief_summary>
	<brief_title>Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination Advanced Pancreatic Cancer</brief_title>
	<detailed_description>HLA-A*02:01-restricted VEGFR1-specific cytotoxic T lymphocyte ( CTL ) response obtain HLA-A2/Kd transgenic murine model . HLA-A*02:01-restricted VEGFR1-specific CTL clone also obtain peripheral blood mononuclear cell healthy volunteer donor . These CTL clone show potent anti-tumor CTL response HLA class Ⅰ-restricted manner vitro . Vaccination HLA-A*02:01-restricted VEGFR1-specific peptide A2/Kd transgenic mouse markedly suppress tumor-induced angiogenesis tumor growth vivo .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Heterozygote homozygote HLAA*02:01 allele Inoperable recurrent pancreatic cancer without prior therapy Difficult continue prior therapy due treatmentrelated toxicity ECOG performance status 02 Evaluable primary metastatic lesion RECIST v.1.0 criterion Clearance period prior therapy 4 week Life expectancy 3 month Laboratory value follow 2,000/μL &lt; WBC &lt; 15,000/μL Platelet count &gt; 100,000/μL AST &lt; 150 IU/L ALT &lt; 150 IU/L Total bilirubin &lt; 3.0 mg/dl Serum creatinine &lt; 3.0 mg/dl Pregnancy ( refusal inability use effective contraceptive ) Breastfeeding Active uncontrolled infection Systemic use corticosteroid immunosuppressant Uncontrollable brain metastasis and/or meningeal infiltration Unhealed external wound Possibilities complicate paralytic ileus interstitial pneumonitis Decision eligible determine principal investigator attend doctor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>cancer</keyword>
	<keyword>pancreas</keyword>
	<keyword>advanced</keyword>
	<keyword>peptide</keyword>
	<keyword>vaccination</keyword>
	<keyword>VEGFR1</keyword>
	<keyword>HLA</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>IFA</keyword>
	<keyword>Cancer Pancreas</keyword>
	<keyword>Neoplasms , Pancreas</keyword>
	<keyword>Pancreas Cancer</keyword>
</DOC>